Neuroprotective role of fucoxanthin against cerebral ischemic/reperfusion injury through activation of Nrf2/HO-1 signaling

Hu, Lixun; Chen, Weimei; Tian, Feng; Yuan, Chao; Wang, Hongjuan; Yue, Hongmei

doi:10.1016/j.biopha.2018.07.088

Cited by 87 publications

(73 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concentrations (12.5–50 µ m ) of FX we tested to mitigate oxLDL‐caused endothelial cell dysfunction are similar to previous studies. For example, 20 µ m of FX was revealed to reduce oxygen‐glucose deprivation and reperfusion‐caused apoptosis in neurons . Wang et al.…”

Section: Resultsmentioning

confidence: 99%

Fucoxanthin Protects against oxLDL‐Induced Endothelial Damage via Activating the AMPK‐Akt‐CREB‐PGC1α Pathway

Chou

Chu

et al. 2019

Molecular Nutrition Food Res

View full text Add to dashboard Cite

Scope: Atherosclerotic cardiovascular disease is the most prevalent cause of mortality and morbidity. Fucoxanthin (FX) possesses anti-hypertensive and anti-obesity properties. However, the molecular mechanisms underlying the inhibitory effects of FX on oxidized low-density lipoprotein (oxLDL)-induced oxidative injuries in human endothelial cells are still largely unknown. This study aims to test the hypothesis that FX protects against oxLDL-induced oxidative stress by upregulating AMP-activated protein kinase (AMPK) and to explore the roles of cAMP response element binding protein (CREB) and peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α).

show abstract

Section: Resultsmentioning

confidence: 99%

Fucoxanthin Protects against oxLDL‐Induced Endothelial Damage via Activating the AMPK‐Akt‐CREB‐PGC1α Pathway

Chou

Chu

et al. 2019

Molecular Nutrition Food Res

View full text Add to dashboard Cite

show abstract

“…daily dose of fucoxanthin oil for It is intended here to review the most relevant in vivo studies with pure fucoxanthin, highlighting the impact that each one had on the process of development of fucoxanthin as a drug with many potential therapeutic uses. Fucoxanthin 22 ( Figure 5) seems to have a neuroprotective effect, as evidenced by Hu et al [140] using the middle cerebral artery occlusion rat model (MCAO) [141]. To assess a neuroprotective effect, the rats were intragastrical administered different doses (30, 60, and 90 mg/kg b.w.)…”

Section: Fucoxanthinmentioning

confidence: 93%

Seaweed Secondary Metabolites with Beneficial Health Effects: An Overview of Successes in In Vivo Studies and Clinical Trials

et al. 2019

View full text Add to dashboard Cite

Macroalgae are increasingly viewed as a source of secondary metabolites with great potential for the development of new drugs. In this development, in vitro studies are only the first step in a long process, while in vivo studies and clinical trials are the most revealing stages of the true potential and limitations that a given metabolite may have as a new drug. This literature review aims to give a critical overview of the secondary metabolites that reveal the most interesting results in these two steps. Phlorotannins show great pharmaceutical potential in in vivo models and, among the several examples, the anti-dyslipidemia activity of dieckol must be highlighted because it was more effective than lovastatin in an in vivo model. The IRLIIVLMPILMA tridecapeptide that exhibits an in vivo level of activity similar to the hypotensive clinical drug captopril should still be stressed, as well as griffithsin which showed such stunning results over a variety of animal models and which will probably move onto clinical trials soon. Regarding clinical trials, studies with pure algal metabolites are scarce, limited to those carried out with kahalalide F and fucoxanthin. The majority of clinical trials currently aim to ascertain the effect of algae consumption, as extracts or fractions, on obesity and diabetes.Studies focusing on the preparation of macroalgae extracts and their chemical characterization revealed a large range of seaweed compounds with very interesting biological activities including antitumor, anti-inflammatory, antimicrobial, antidiabetic, antivirus, antihypertensive, fat-lowering, and neuroprotective activities [12][13][14][15].The large volume of studies proving the seaweed compound activities in in vitro systems [16][17][18][19] hints the need for further advancements in the knowledge about macroalgae compound efficiency in living systems (in vivo) and their use in the development of pharmaceuticals. In vitro studies are very relevant and yield very important information, but they only represent the first step of a long process, and the results obtained rarely reveal anything about the effects of a compound in vivo, because the responses observed in vitro can be magnified, diminished, or totally different in a more complex and integrated system. In fact, in vivo studies and clinical trials are those which contribute most to truly understanding the real potential of compounds as future pharmaceuticals.In this regard, the present work intends to present insight into the results obtained in the last few years regarding secondary metabolites, such as phlorotannins, halogenated compounds, fucoxanthin, and fucosterol isolated from macroalgae, involved in in vivo studies and clinical trials, identifying the research opportunities and knowledge gaps, to valorize these compounds and their natural resources. The intention is not to present an exhaustive survey of all published works, but rather a selection of authors based on the following criteria: in-depth studies involving pure compounds most characteristic f...

show abstract

“…However, it is unknown if fucoxanthin crosses the blood-brain barrier. Despite limited information on fucoxanthin and the blood-brain barrier permeability, experiments have been performed that show that animals who undergo middle cerebral artery occlusion (MCAO) demonstrate brain tissue damage associated with apoptosis and neurological deficits, but fucoxanthin treatment reverses this MCAO-induced brain injury [188]. Treatment with fucoxanthin improves cognitive and motor function in animals challenged by neurodegeneration and ischemic insults [183,188,189].…”

Section: Fucoxanthinmentioning

confidence: 99%

Anti-Apoptotic Effects of Carotenoids in Neurodegeneration

et al. 2020

View full text Add to dashboard Cite

Apoptosis, programmed cell death type I, is a critical part of neurodegeneration in cerebral ischemia, Parkinson’s, and Alzheimer’s disease. Apoptosis begins with activation of pro-death proteins Bax and Bak, release of cytochrome c and activation of caspases, loss of membrane integrity of intracellular organelles, and ultimately cell death. Approaches that block apoptotic pathways may prevent or delay neurodegenerative processes. Carotenoids are a group of pigments found in fruits, vegetables, and seaweeds that possess antioxidant properties. Over the last several decades, an increasing number of studies have demonstrated a protective role of carotenoids in neurodegenerative disease. In this review, we describe functions of commonly consumed carotenoids including lycopene, β-carotene, lutein, astaxanthin, and fucoxanthin and their roles in neurodegenerative disease models. We also discuss the underlying cellular mechanisms of carotenoid-mediated neuroprotection, including their antioxidant properties, role as signaling molecules, and as gene regulators that alleviate apoptosis-associated brain cell death.

show abstract

Neuroprotective role of fucoxanthin against cerebral ischemic/reperfusion injury through activation of Nrf2/HO-1 signaling

Cited by 87 publications

References 18 publications

Fucoxanthin Protects against oxLDL‐Induced Endothelial Damage via Activating the AMPK‐Akt‐CREB‐PGC1α Pathway

Fucoxanthin Protects against oxLDL‐Induced Endothelial Damage via Activating the AMPK‐Akt‐CREB‐PGC1α Pathway

Seaweed Secondary Metabolites with Beneficial Health Effects: An Overview of Successes in In Vivo Studies and Clinical Trials

Anti-Apoptotic Effects of Carotenoids in Neurodegeneration

Contact Info

Product

Resources

About